Nasdaq Bear Market: 5 Sensational Growth Stocks You'll Regret Not Buying on the DipThe Motley Fool • 04/22/23
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for ChangeBusiness Wire • 04/05/23
Exelixis Targeted as Activist Farallon Capital Partners Reveals 7.2% Holding24/7 Wall Street • 03/22/23
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes SummitBusiness Wire • 03/13/23
Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the DipThe Motley Fool • 03/11/23
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney CancerBusiness Wire • 03/02/23
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the DipThe Motley Fool • 02/18/23
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid TumorsBusiness Wire • 02/13/23